Nucleoside is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection. 

HIV

• A medication guide and warning card should be dispensed with each new prescription and refill.
• Adults: 600 mg daily, administered as either 300 mg twice daily or 600 mg once daily.
• Pediatric Patients Aged 3 Months and Older: Dose should be calculated on body weight (kg) and should not exceed 300 mg twice daily
• Patients With Hepatic Impairment:
  • Mild hepatic impairment – 200 mg twice daily
  • moderate/severe hepatic impairment- contraindicated.

The most commonly reported adverse reactions were-

• nausea
• headache
• malaise 
• fatigue
• dreams/sleep disorders

The most commonly reported adverse reactions of at least moderate intensity in pediatric HIV-1 clinical studies were-

• fever and/or chills
• nausea and vomiting
• skin rashes
• ear/nose/throat infections

Nausea	Headache	Fatigue
Sleeping Disorder	Fever	Rash

• ZIAGEN has been linked to serious, and sometimes fatal, hypersensitivity reactions.
• Abacavir hypersensitivity is a multi-organ clinical syndrome.
  Patients who have the HLA-B*5701 allele are more likely to have a hypersensitivity reaction to abacavir.
• If a hypersensitivity reaction is suspected, discontinue ZIAGEN immediately. If hypersensitivity cannot be ruled out, regardless of HLA-B*5701 status, discontinue ZIAGEN permanently, even if other diagnoses are possible.
• NEVER restart ZIAGEN or any other abacavir-containing product after a hypersensitivity reaction.
• The use of nucleoside analogues has been linked to lactic acidosis and severe hepatomegaly with steatosis, including fatal cases.
• In patients receiving combination antiretroviral therapy, immune reconstitution syndrome and redistribution/accumulation of body fat have been reported.